Breaking News

Astellas Pharma Adds Medical Expertise

October 22, 2013

Weinberg and McGarry to head global clinical science and medical safety

Mark Weinberg, M.D. has been promoted to vice president of Global Clinical Science, and Robin J. McGarry, M.D. has been appointed vice president, global medical safety head at Astellas Pharma Global Development, Inc. (APGD).
Dr. Weinberg joined the company in 2011 as the global therapeutic area head in CNS and Pain. He has more than 14 years of experience in the pharmaceutical industry, working across multiple therapeutic areas. Prior to Astellas he was at Lundbeck, where he focused on CNS.   
Dr. McGarry has more than 25 years of experience in the pharmaceutical industry, including positions in clinical development and medical affairs, and served as vice president, Worldwide Safety at Pfizer. For the past 13 years, she has worked as an independent consultant, providing pharmacovigilance, clinical, and regulatory strategic consulting services. 

"Since its inception in 2008, APGD has been a driving force in Astellas' mission of developing innovative medicines for patients in need, said Dr. Sef Kurstjens, chief medical officer of Astellas and president of APGD. "We are thrilled to be promoting Mark and bringing Robin onto the Astellas team to further that mission."
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks